Top

The European Journal of Health Economics

Published in:

01-02-2009 | Original paper

SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility

Authors: Richard Grieve, Marina Grishchenko, John Cairns

Published in: The European Journal of Health Economics | Issue 1/2009

Abstract

The choice of instrument (e.g. EQ-5D vs. SF-6D) can lead to different health-related utility scores, but it is unclear why these differences arise and whether they change cost utility analysis (CUA) results. This paper addresses these issues using a case study where using SF-6D rather EQ-5D led to greater utility gain and a lower cost per QALY for treatment. The paper examines reasons for this difference. This paper finds that an important factor was the inclusion in the SF-6D descriptive system of separate items for “vitality” and “social functioning”, not explicitly included in EQ-5D. Further studies are required that examine the impact of the choice of instrument on cost-utility.

Barton, G.R., Bankart, J., Davis, A.C., Summerfield, Q.A.: Comparing utility scores before and after hearing-aid provision: results according to the EQ-5D, HUI3 and SF-6D. Appl. Health Econ. Health Policy 3(2), 103–105 (2004)CrossRef

Bharmal, M., Thomas, J. 3rd.: Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 9(4), 262–271 (2006)CrossRef

Boonen, A., van der Heijde, D., Landewe, R., van Tubergen, A., Mielants, H., Dougados, M., van der Linden, S.: How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Ann. Rheum. Dis. 66(6), 771–777 (2007)CrossRef

Brazier, J., Roberts, J., Deverill, M.: The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21, 271–292 (2002)CrossRef

Brazier, J., Roberts, J., Tsuchiya, A., Busschbach, J.: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 13, 873–884 (2004)CrossRef

Bryan, S., Longworth, L.: Measuring health-related utility: why disparity between EQ-5D and SF-6D? Eur. J. Health Econ. 6, 253–260 (2005)CrossRef

Dolan, P.: Modelling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)CrossRef

Fisk, J.D., Brown, M.G., Sketris, I.S., Metz, L.M., Murray, T.J., Stadnyk, K.J.: A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J. Neurol. Neurosurg. Psychiatry 76, 58–63 (2005)CrossRef

Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L. Jr., et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975–982 (2002)CrossRef

10.

Grieve, R., Roberts, J., Wright, M., Sweeting, M., De Angelis, D., Rosenberg, W., Bassendine, M., Main, J., Thomas, H.: Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 55, 1332–1338 (2006)CrossRef

11.

Lamers, L.M., Bouwmans, C.A.M., van Straten, A., Donker, M.C.H., Hakkaart, L.: Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ. 15, 1229–1236 (2006)CrossRef

12.

Longworth, L., Bryan, S.: An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 12, 1061–1067 (2003)CrossRef

13.

Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V., Shiffman, M., Reindollar, R., et al.: PegInterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958–965 (2001)CrossRef

14.

Mara, C.A., Woolcott, J.C., Kopec, J.A., Shojania, K., Offer, R., Brazier, J.E., Esdaile, J.M., Anis, A.H.: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60, 1571–1582 (2005)CrossRef

15.

Michaels, J.A., Campbell, W.B., Brazier, J.E., Macintyre, J.B., Palfreyman, S.J., Ratcliffe, J., Rigby, K.: Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial). Health Technol. Assess. 10(13), 1–196 (2006)

16.

National Institute for Clinical Excellence: Guide to the Methods of Technology Appraisal. NICE, London (2004)

17.

Pickard, S.A., Wang, Z., Walton, S.M., Lee, T.A.: Are decisions using cost-utility analyses robust to the choice of SF-36/SF-12 preferenced-based algorithm? BMC Health Qual. Life Outcomes 3, 1–9 (2005)CrossRef

18.

Stavem, K., Frøland, S.S., Hellum, K.B.: Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual. Life Res. 14, 971–980 (2005)CrossRef

19.

Tidermark, J., Bergström, G., Svensson, O., Törnkvist, H., Ponzer, S.: Responsiveness of the EuroQol (EQ 5-D) and the SF-36 in elderly patients with displaced femoral neck fracture. Qual. Life Res. 12(8), 1069–1079 (2003)CrossRef

20.

Tsuchiya, A., Brazier, J., Roberts, J.: Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets. J. Health Econ. 25, 334–346 (2006)CrossRef

21.

van den Hout, W.B., de Jong, Z., Munneke, M., Hazes, JMW., Breedveld, F.C., Vliet Vlieland, T.P.M.: Cost-utility and cost-effectiveness analyses of a long-term, high-intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis. Arthritis Rheum. 53, 39–47 (2005)CrossRef

22.

van Stel H.F., Buskens, E.: Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual. Life Outcomes 4, 1–9 (2006)CrossRef

23.

Xie, F., Li, S.C., Luo, N., Lo, N.N., Yeo, S.J., Yang, K.Y., Fong, K.Y., Thumboo, J.: Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement. Arthritis Rheum. 57(6), 1043–1049 (2007)CrossRef

24.

Wee, H.L., Machin, D., Loke, W.C., Li, S.C., Cheung, Y.B., Luo, N., Feeny, D., Fong, K.Y., Thumboo, J.: Assessing differences in utility scores: a comparison of four widely used preference-based instruments. Value Health 10(4), 256–265 (2007)CrossRef

25.

Wright, M., Grieve, R., Roberts, J., Main, J., Thomas, H.C., UK Mild Hepatitis C Trial Investigators: Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol. Assess. 10(21), 1–113 (2006)

Title: SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility
Authors: Richard Grieve
Marina Grishchenko
John Cairns
Publication date: 01-02-2009
Publisher: Springer-Verlag
Published in: The European Journal of Health Economics / Issue 1/2009
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-008-0097-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

A comparison between willingness to pay and willingness to give up time

Can we afford to ignore missing data in cost-effectiveness analyses?

The quality of life of Palestinians living in chronic conflict: assessment and determinants

The relationship between the Balanced Budget Act and length of stay for Medicare patients in US hospitals

Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects

Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany